# Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients

> **NCT03733691** · PHASE2 · TERMINATED · sponsor: **Oncotherapeutics** · enrollment: 19 (actual)

## Conditions studied

- Newly Diagnosed Multiple Myeloma

## Interventions

- **DRUG:** Ixazomib
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT03733691
- **Lead sponsor:** Oncotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-01
- **Primary completion:** 2023-10-19
- **Final completion:** 2023-10-19
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Insufficient enrollment
- **Last updated:** 2023-10-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03733691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03733691, "Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03733691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*